According to the data published by Australian Institute of Health and Welfare 2021, in Australia the average age of first-time mothers increased from 27.9 years in 2009 to 31.9 years in 2019. With the median age for first-time mothers increasing, a growing number of women are expected to face difficulties in conceiving naturally. In this scenario, an increasing number of women are forced to opt for IVF treatments; this is expected to drive the growth of the IVF market in the coming years.
More than 2.5 million vitro fertilization (IVF) cycles are performed every year worldwide. The cost of IVF treatment varies from country to country due to the lack of reimbursement policies. A lack of insurance coverage and the poor reimbursement scenario in some parts of the world are limiting the growth of this market.
For More Info, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89198891
COVID-19 pandemic triggered the worldwide suspension of in vitro fertilization treatment; this had a profound impact on women undergoing IVF procedures. In India, 30 lakh people seek IVF every year, but only 5 lakh people undergo IVF/intrauterine insemination (IUI) procedures.
During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles worldwide. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who had opted for IVF treatment before the pandemic.
The prominent players operating in the global in vitro fertilization market include The Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher Scientific, Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker Company, Inc. (US), Kitazato Corporation (Japan), Corning Corporation (US), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium), and Eppendorf (Germany).